Ollin Biosciences, a clinical-stage biopharmaceutical company dedicated to acquiring and developing therapies for vision-threatening diseases, has secured a substantial $330.0M in Series b funding. The capital infusion will further its mission to bring best-in-disease treatments to market.
With a differentiated pipeline and a world-class team, Ollin aims to redefine what’s possible in ophthalmology. This latest round underscores strong investor confidence in the company's innovative approach to tackling critical vision impairments.
